A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC
Latest Information Update: 04 Mar 2024
At a glance
- Drugs Osimertinib (Primary) ; Savolitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms SANOVO
- Sponsors HUTCHMED
- 28 Feb 2024 According to a HUTCHMED Media Release, enrollment Completion expected in late 2024.
- 16 Aug 2023 According to an AstraZeneca media release, results from this study will be presented at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC), 9 to 12 September 2023.
- 09 Aug 2022 Trial design presented at the 2022 World Conference on Lung Cancer